Discovery and Validation of Wilms Tumor Markers Using Urine Proteomics
N/A
N/A
Both
Kidney Cancer
Trial Information
Discovery and Validation of Wilms Tumor Markers Using Urine Proteomics
OBJECTIVES:
- To validate the prognostic performance of specific-candidate Wilms tumor markers by
measuring their urinary concentration using enzyme-linked immunosorbent assays (ELISAs)
in urine specimens collected at diagnosis from 50 patients with favorable histology
Wilms tumor who relapsed and 50 patients who did not relapse.
OUTLINE: Urine specimens are analyzed using enzyme-linked immunosorbent assays (ELISAs) for
biomarkers.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Urine specimens collected at diagnosis will be selected from patients with stage
II-III Wilms tumors, with both local and non-local sites of disease relapse
- Clinical patient information (urinalysis/macro, age, gender, congenital
defects/syndromes, comorbidities, tumor stage, size, pathology, therapy, outcome)
available
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Wilms tumor biomarkers identified by ELISA
Safety Issue:
No
Principal Investigator
Elizabeth A. Mullen, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Dana-Farber Cancer Institute
Authority:
United States: Federal Government
Study ID:
CDR0000727337
NCT ID:
NCT01550393
Start Date:
March 2012
Completion Date:
Related Keywords:
- Kidney Cancer
- stage II Wilms tumor
- stage III Wilms tumor
- recurrent Wilms tumor and other childhood kidney tumors
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Wilms Tumor
Name | Location |
|---|
